Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion late Monday. Inari stock catapulted on the news.

Fintel reports that on January 7, 2025, Canaccord Genuity downgraded their outlook for Inari Medical (NasdaqGS:NARI) from Buy to Hold. Analyst Price Forecast Suggests 4.91% Upside As of December 23, ...

Charles R. Goulding and Preeti Sulibhavi examine how Stryker's acquisition of Inari Medical is set to transform vascular care ...

Stryker's acquisition of Inari for $4.9B enhances its neurovascular ... has not really been a player in venous markets like pulmonary embolism (or PE), deep vein thrombosis (or DVT), limb ischemia ...

Stryker acquires Inari Medical for $80/share ... for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism. Also Read: Morgan Stanley Maintains Positive MedTech Outlook ...

and pulmonary embolism (PE), where blood clots form in the veins and can travel to the lungs. Central Venous Catheter (CVC): A tube placed in a large vein to give medications, fluids, or to ...

As of December 3, 2024, the average one-year price target for Inari Medical is $66.15/share ... deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the ...